Sierra Oncology, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Sierra Oncology, Inc.
Public Company Edition: Also, Teva sells $2.1bn in notes to pay prior debts. In restructurings, Baudax splits off from Recro, while three firms shift their focus to specific cell therapy programs.
Novartis has taken an option on novel inhibitors of the KRAS cell signaling pathway while it funds the drug discovery research at the Cancer Research UK’s Beatson Institute.
Public Company Edition: Jefferies report notes robust IPO market, but SVB Leerink predicts a financing slowdown. Also, Mirati raises cash for KRAS programs after Amgen's ASCO data and a strategic shift results in job cuts at ImmunoGen.
Partnership will use Carna’s proprietary lipid kinase drug discovery platform, bringing another aspect to Gilead’s IO efforts. Catalent continues expansion by acquiring Novavax R&D assets; Genfit licenses elafibranor in China to Terns.
- Drug Delivery
- Antisense, Oligonucleotides
- Drug Discovery Tools
- Large Molecule
- Other Names / Subsidiaries
- ProNAi Therapeutics, Inc.